Navigation Links
Massachusetts General Hospital leading nationwide, comparative study of common bipolar medications
Date:1/20/2011

The Massachusetts General Hospital (MGH) Bipolar Clinic and Research Program with the Bipolar Trials Network is launching Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness), a 10-site nationwide trial evaluating the real-world advantages and disadvantages of quetiapine, a widely prescribed second generation antipsychotic mood stabilizing medication, compared to lithium, the gold standard mood stabilizer, for the treatment of outpatients with bipolar disorder. The study is funded by a $10 million grant from the Agency for Healthcare Research Quality (AHRQ).

Bipolar disorder is a lifelong and highly recurrent mood disorder characterized by episodes of mania or hypomania that alternate with episodes of major depression. It is among the top 10 causes of disability worldwide, with associated costs of $70.6 billion per year for treatment and prevention.

"Studies that compare treatments for bipolar disorder usually don't allow participants to take other medications, but most patients need about three medications to feel well and stay well. Bipolar CHOICE is unique because participants can be treated not only with quetiapine or lithium, but with almost any other medication except other antipsychotics in order to help them feel better," says Andrew A. Nierenberg, MD, director of the MGH Bipolar Research Program and the principal investigator of Bipolar CHOICE.

Over the past 10 years, the pharmacologic treatments for bipolar disorder have shifted away from lithium which is available as a generic medication in favor of newly developed antipsychotics, such as quetiapine. Both drugs have well documented side effects. Quetiapine has the risk of drowsiness, weight gain, and increases the risk of cardiovascular disease. Lithium is associated with the risk of long-term thyroid and kidney problems.

"A real-world effectiveness study may uncover considerable differences regarding the risks of adverse effects, costs, and adherence to treatment. If such differences are found, the results of this study would have immediate and profound implications for clinical treatment decisions," says Louisa Sylvia, PhD, director of Clinical Operations of Bipolar CHOICE.

The AHRQ grant is part of an investments made under the American Recovery and Reinvestment Act of 2009, which designated $1.1. billion to support patient-centered outcomes research. This research is designed to inform health care decisions by providing evidence and information on the effectiveness, benefits and harms of different treatment options.


'/>"/>

Contact: Jennifer Gundersen Harris
jgundersen1@partners.org
617-724-6433
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Massachusetts Hospital Agrees to Pay U.S. $2.79 Million to Resolve False Claims Act Allegations
2. Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
3. Elements Therapeutic Massage Announces Franchise Expansion Plan for Massachusetts
4. Miles for Hope’s Moving Towards A Cure(SM) Brain Tumor Walk in Boston Raising Funds for Brain Tumor Vaccine and Massachusetts General Hospital
5. Massachusetts health care reform reviewed as a model for national plan
6. Firefighters Walk Over 60,000 Miles in Blue Cross Blue Shield of Massachusetts' Fitness Challenge
7. Blue Cross Blue Shield of Massachusetts Demonstrates Community Commitment with Fifth William C. Van Faasen Community Service Sabbatical
8. Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract
9. Doctors hard to find for patients in Massachusetts first for-profit health plan
10. Massachusetts Institute of Technology IDs new cancer drug target
11. Massachusetts physician groups improving patient experience, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
(Date:6/23/2016)...  The National Pharmaceutical Council (NPC) today announced ... research organization as its newest member.  ... president and chief scientific officer, Mallinckrodt Pharmaceuticals, will ... Board of Directors. ... us in support of our efforts to conduct ...
Breaking Medicine Technology: